Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Southern Denmark | OTHER |
| UiT The Arctic University of Norway | OTHER |
Not provided
Not provided
Not provided
Not provided
This study investigated the cellular and molecular characteristics of AT-MSCs obtained from autologous AT therapy in patients with high transphincteric perianal fistulas of crytoglandular origin. Adipose tissue was injected into anal fistulas. Characteristics of adipose tissue mesenchymal stemcells (AT-MSC) was investigated and compared in patients with fistula that healed after the treatment (responders) to patients who failed to heal (non-responders)
Injection with allogene or autologous stem cells has been reported to be efficient treatment of perianal fistulas. An alternative to this treatment could be injection with freshly collected autologous adipose tissue. In this study 27 patients with cryptoglandular anal fistulas were treated with freshly collected autologous adipose tissue.A clinical assessment of the patient prior to inclusion was undertaken and a loose seton placed for at least 6 weeks prior to fat injection. An MRI of the pelvis was performed before inclusion. Fistulas with secondary tracts and/or cavities were excluded. The operation was performed in one procedure including liposuction and injection of adipose tissue. A sample of adipose tissue from all 27 patients was analyzed. AT-MSCs were isolated and characterized using cellular and molecular analyses. Clinical and MRI-scanning evaluation of fistula healing and evaluation of ano-rectal function was performed after 6 months. AT-MSCs phenotype was compared between responders and non-responders with respect to fistula healing. The evaluation of the AT-MSCs was performed in a blinded manner.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Injection with adipose tissue | Experimental | Injection of freshly collected autologous adipose tissue |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Injection of autologous adipose tissue in anal fistula | Procedure |
|
| Measure | Description | Time Frame |
|---|---|---|
| Investigation of cell proliferation of AT-MSCs | Cell proliferation of AT-MSCs evaluated as number of cells/per day | At start of treatment |
| Investigation of differentiation potential of AT-MSCs to differentiate into adipocyte | Differentiation potential of AT-MSCs: to differentiate into adipocyte measured by Oil-Red O staining and gene expression of adipogenic markers (PPARg and LPL normalized to housekeeping gene beta actin) presented as a Fold change to undifferentiated cells (arbitrary units) | At start of treatment |
| Investigation of differentiation potential of AT-MSCs to differentiate into osteoblast | Differentiation potential of AT-MSCs: to differentiate into osteoblast measured by Alizarin S staining and gene expression of osteogenic markers (BGALP and RUNX2 normalized to housekeeping gene beta actin) presented as a Fold change to undifferentiated cells (arbitrary units) | At start of treatment |
| Measurement of gene expression profile of AT-MSCs | Gene expression of proinflammatory (NFKB, TNFa, IL1B, IL6) and senescence associated molecules(CDKN2A, TP53, TGFB1, VEGFA, IFNG, IL6) of AT-MSCs in relation to the outcome of fistula treatment (i.e. comparison between responders and non-responders). The data are normalized to housekeeping gene beta actin (arbitrary units) | At start of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Healing of anal fistula after treatment | Clinical healing defined as closure of the internal and external fistula opening and no discharge evaluated as success rate of the healing in (%) | 6 months after last injection of autologous adipose tissue |
| Evaluation of fistula healing after treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Anovaginal fistula
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34819138 | Derived | Tencerova M, Lundby L, Buntzen S, Norderval S, Hougaard HT, Pedersen BG, Kassem M. Molecular differences of adipose-derived mesenchymal stem cells between non-responders and responders in treatment of transphincteric perianal fistulas. Stem Cell Res Ther. 2021 Nov 24;12(1):586. doi: 10.1186/s13287-021-02644-8. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Characterisation of adipose tissue (AT-MSCs) was performed blinded to the result of the treatment responder/non-responder
Not provided
A combination of Clinical and MRI healing defined as closure of the internal and external fistula opening and no discharge and no fluid filled fistula tracts on evaluated as success rate of the healing in (%) |
| 6 months after last injection of autologous adipose tissue |
| Functional gastroenterological outcome after treatment | Anal continence evaluated as the St. Mark's Score (0-24) | 6 months after last injection of autologous adipose tissue |
| Defecation disorder evaluation after treatment | Defecation disorders evaluated as Altomare Obstructed Defecation Score (0-31) | 6 months after last injection of autologous adipose tissue |
| Functional urological outcome after treatment | Urinary incontinence evaluated as ICIQ-UI-SF (0-21) | 6 months after last injection of autologous adipose tissue |